The key reason why Opiant Pharmaceuticals (NASDAQ: OPNT) share rocketed in the pre-market session

Opiant Pharmaceuticals (NASDAQ: OPNT) stock surged 13.93% to $9.65 in the pre-market trading after the company reported that the Biomedical Applied Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response in the United States, has an additional contribution of up to $3.5 million.

To advance OPNT003, nasal nalmefene, for opioid overdose, Department of Health and Human Services. The contract adjustment raises the BARDA contract’s gross future value to $8.1 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

In addition to the $7.4 million grant, Opiant received from the National Institute on Drug Abuse, an earlier award from BARDA of up to $4.6 million will also support the clinical development and U.S. regulatory submission OPNT003.

BARDA’s additional support will help fund a planned study of the pharmacodynamic systems in healthy volunteers and research related to Aptar Pharma’s Unit Dose System.

Related posts